Background Recurrent acute respiratory tract infections (ARTI) are a common problem in childhood. Some evidence suggests a benefit regarding the prevention of ARTI in children treated with the immunomodulator OM-85 BV (Bronchovaxom). Methods We summarised the evidence on the effectiveness of the immunomodulator OM-85 BV in the prevention of ARTI in children. We searched randomised comparisons of oral purified bacterial extracts against inactive controls in children with respiratory tract diseases in nine electronic databases and reference lists of included studies. We extracted salient features of each study, calculated relative risks (RR) or weighted mean differences (WMD) and performed meta-analyses using random-effects models. Results Thirteen studies (2,721 patients) of low to moderate quality tested OM-85 BV. Patients and outcomes differed substantially, which impeded pooling results of more than two trials. Two studies (240 patients) reporting on the number of patients with less than three infections over 6 month of follow-up in children not in day care showed a trend for benefit RR 0.82 (95% CI, 0.65-1.02). One out of two studies examining the number of children not in day care without infections over 4-6 month reported a significant RR of 0.42 (95% CI, 0.21-0.82) whereas the smaller, second study did not [RR 0.92 (95% CI,]. Two studies reporting the number of antibiotic courses indicated a benefit for the intervention arm [WMD 2.0 (95% CI,3)]. Two out of the three studies showed a reduction of length of episodes of 4-6 days whereas a third study showed no difference between the two groups. Conclusion Evidence in favour of OM-85 BV in the prevention of ARTI in children is weak. There is a trend for fewer and shorter infections and a reduction of antibiotic use.
airway tract infections are caused by viruses. However, several bacterial complications can appear, such as acute otitis media, sinusitis and bronchitis. Therefore, physicians are prone to prescribe antibiotics to treat ARTI although only a small proportion of children will benefit from this treatment. Due to this over-prescription, many bacteria have become resistant against commonly prescribed antibiotics. To overcome this treatment dilemma, several authors proposed changing the treatment strategy of ARTI from acute intervention to prophylaxis of recurrence using vaccines and immunomodulating agents [10] . Defects in the immunological system, such as selective immunoglobulin A (IgA) deficiency, are known to be linked with frequent respiratory infections by bacteria and viruses. From an epidemiologic point of view, it has been shown that over 50% of children with three or more episodes a year during at least 2 years were deficient in one of the IgG subclasses and that 17% were IgA deficient [4] .
OM-85 BV (Bronchovaxom, OM Pharma, Geneva Switzerland), an orally administered immunostimulator (capsules of 3.5 mg) containing lyophilised bacterial fractions of Haemophilus influenzae, Diplococcus pneumoniae, Klebsiella pneumoniae and K. ozaenae, Staphylococcus aureus, Streptococcus pyogenes and S. viridans and Moraxella catarrhalis, provokes a local immune response via activation of the mucosa-associated lymphoid tissue and stimulates the production of salivary and bronchoalveolar serum IgA as well as serum IgA and IgG. It has been widely used in several European countries in children and adults assuming it will prevent recurrences of respiratory tract infections (RTIs). In adult patients with chronic bronchitis and chronic obstructive pulmonary disease (COPD), a systematic review could not find a preventive effect on exacerbations [22] . Recent clinical studies in children reported on significantly reduced rates of RTIs with good safety and tolerance [9, 18] . Up to now, however, the literature has not been assembled and appraised but is scattered and not easy to access. Furthermore, results from these studies are imprecise. We therefore performed a systematic review to investigate the efficacy and harm of these immunostimulating drugs in the prophylaxis of ARTI in children.
Methods
Our review was based on a prospective protocol using widely recommended methodology [1, 7] .
Data sources
We searched in Medline, Premedline, EMBASE, Lilacs, Biosis, CINAHL, HealthStar, Inspec and the Cochrane Controlled Trials Register without language restriction using combinations of the terms OM-85 BV, Bronchovaxom, Luivac bacterial and lysate immunotherapy, respiratory tract disease. Searches were limited to "human". The last electronic search was in April 2005. Searches were complemented by screening reference lists of included reports and of relevant review articles, contacting authors of included reports and contacting two manufacturers of bacterial lysates: OM Pharma, Switzerland, and Sankyo Pharma, Switzerland, for additional trials and unpublished data.
Study selection
Reports were considered if they described randomised controlled trials of an oral bacterial extract (active) compared with an inactive control (placebo or no treatment) in children with respiratory tract diseases. Relevant studies had to report on clinical endpoints of efficacy or harm. Studies on immunological parameters were not considered. There was the intention to consider data from abstracts of scientific meetings if the study methods were clearly described and data reporting was adequate.
Validity assessment
One author (CS) screened all retrieved reports. Three authors (LL, CS, LMB,) assessed the selected studies for methodological quality using components of study design that would ensure internal validity [1] . Information was sought for the adequacy of patient enrolment, sequence generation, concealment of allocation, blinding (patient, caregiver, outcome assessment, data analysis), a statement on how dropouts were handled and details to enable intention-to-treat analysis (maximum score 6 points). We sought information on these aspects because random allocation of subjects (with concealment of allocation sequence) prevents selection bias and ensures that comparison groups are balanced on average for known, unknown and unmeasured confounding variables [19, 20] . Blinding statisticians to group allocation was used, as it prevents bias in analysis. An intention-to-treat analysis is important in preventing attrition bias by considering data for all patients, including those who dropped out. Discrepancies were resolved by discussion.
Data extraction
Information about bacterial lysate regimens (drug, dose, route of administration, duration of treatment), number of patients enrolled and analysed, length of follow-up, and outcome measures were entered in standard collection sheets. Particular attention was given to specifying whether children attended day schools since previous studies identified an increased risk for upper respiratory infections in those children. This was done by one investigator (LL) and cross-checked by two others (LMB, CS). The primary outcome measure was prevention of ARTI. An upper ARTI was defined as the presence of at least one of the following signs: rhinorrhea, sore throat or cough. Lower ARTI was defined as the presence of at least one of the following signs: rales or crepitations, wheezing, pathologic respiratory rate or stridor. If not defined in detail in the original study, information about infections was taken as reported in the original trials. Secondary outcome measures were symptom duration and improvement as assessed by the observers and the patients, rate of hospitalisation due to infections, reduction of antibiotic requirements, school absences and adverse effects.
Analysis
From each study, outcome data and data on harm were abstracted into 2×2 tables. Heterogeneity (i.e. differences between studies) of risk ratios was assessed graphically using forest plots and statistically using the chi-squared test to aid in decisions on how to proceed with quantitative synthesis. This formal statistical analysis examined whether the observed variation in study results was compatible with the variation expected by chance alone. Exploration of the causes of heterogeneity was planned using variation in features of the population (inclusion and exclusion criteria) intervention (drug regimens) and study outcome and quality. If appropriate, we planned to perform meta-analysis where relative risks from individual studies would be pooled using a fixed effects model if no heterogeneity was detected. In case of heterogeneity, we decided to pool using a random effects model [5] . Results are presented as weighted mean differences (WMD), relative risks (RR) and corresponding 95% confidence intervals. Statistical analy- 
Results
Our searches identified 520 references out of which 465 were subsequently excluded after screening of titles and abstracts (where available). Full texts of the remaining 55 articles were obtained and evaluated for inclusion in the review. Ultimately, 13 studies including 2,721 patients fulfilled our inclusion criteria. (For details, see Fig. 1 ) Nine studies [3, 6, 9, 11, 13, 15, 18, 21, 23] were published in English, two [16, 17] in German, one [14] in French and one [8] in Spanish. There was a large variety in reported endpoints. Four trials [9, 11, 18, 21] reported on absences from school, nine [3, 6, 8, 9, 11, 16, 17, 21, 23] [8, 9, 11, [15] [16] [17] 23] reported the number of antibiotic courses. Only two trials [8, 23] reported about the improvement of symptoms, and no study reported hospitalisation rate due to infections.
Methodological quality
All trials were placebo controlled; there were no head-tohead comparisons. In general, methodological quality was poor to moderate ( Table 1 ). The median score was 2.69; no trial scored 6 and only three trials scored 5 [6, 9, 18] ( Table 2) . Five studies [6, 9, 11, 16, 18] reported on consecutive patient enrolment, and four [3, 6, 9, 18] reported on details of generation of random sequence and concealment of treatment allocation. All studies but one [21] included a statement on how they dealt with dropouts and were using an intention-to-treat analysis. Only four studies [6, 9, 11, 18] , however, provided details about blinding of patients and caregivers. Ten trials (76.92%) [3, 6, 8, 9, 11, 14, 15, 18, 21, 23] acknowledged sponsorship by a manufacturer; in one study [8] , one author was collaborator of a manufacturer.
Patients
Nine trials reported on demographic data [3, 6, 8, 9, 11, [15] [16] [17] [18] 23] ; there were more females than males (767 females vs. 700 males). Inclusion criteria were three or more infections in the previous 6 months in six trials [6, 9, 11, Pooling these two studies using a random-effects model resulted in a non-significant effect of OM-85 BV 15, 16, 18] ; no anatomic alterations of the respiratory tract in four [6, 8, 9, 11] ; no treatment with corticosteroids, immunostimulants or immunosuppressants in eight [3, 6, 9, 11, [15] [16] [17] [18] and no chronic respiratory disease, autoimmune diseases or liver or kidney failure in five [6, 8, 9, 11, 18] ( Table 2 ).
Efficacy endpoints
Although several studies reported on the same outcome category, variation in outcome parameter (e.g. less than six infections vs. less than three infections) impeded combining results of more than two trials. Two studies (240 patients) reported on the number of patients with less than three infections over 6 months of follow-up in children not in day care [13, 18] . The two studies showed a trend for benefit (RR 0.82; 95% CI 0.65-1.02) (Fig. 2a) . Two studies reported on the number of patients without infections over 4-6 months in children not in day care. In one study, the number of infections over 4-6 months was significantly reduced (RR 0.42; 95% CI 0.21-0.82) [15] . The other smaller study did not show a beneficial effect (RR 0.92; 95% CI 0.58-1.46) [14] (pooled RR using a random-effects model 0.64 (95%CI 0.26-1.57) (Fig. 2b) . Three studies [8, 17, 23] reported on duration of episodes. Two out of the three showed a reduction of 4-6 days whereas one study showed no difference between the two groups (Fig. 3) . Finally, two studies [9, 11] reporting on the number of antibiotic courses indicated a benefit for the intervention arm [WMD 2.0 (95% CI, 1.7-2.3)]. (For the complete list of assessed endpoints, see Table 1.) Adverse events Nine studies reported on gastrointestinal, urinary tract, skin and allergic adverse effects [3, 6, 9, 11, [15] [16] [17] [18] 23] . Paupe [15] reported diarrhoea in one patient in the active group and two patients in the control group. In the study of Schaad [18] , adverse reactions in the OM-85 group were diarrhoea (two patients), abdominal pain (two patients), fatigue, urinary frequency (twice in the same patient) and exanthema. In the placebo group, there was one allergic reaction. In Schaad [17] , there was one case of urticaria in the control group; no adverse event was reported in the Bronchovaxom group. Collet [3] recorded 17 medical events for the treated group and 19 for the placebo group. The adverse effects were very infrequent and appeared unlikely to be related with the study medication. Del Rio Navarro [6] recorded eight patients in the active group with ten adverse events; only three were related to drug administration: gastroenteritis, gastroenteritis with melena and diarrhoea. Nine patients taking placebos had ten adverse effects; four were related to the administration of the placebo: gastritis, diarrhoea (trial withdrawal), vomit and asthma. Riedl-Seifert [16] recorded eight patients in the active group with gastrointestinal symptoms: three with skin problems and one with other side effects. In the placebo group were five patients with gastrointestinal manifestations and one patient with skin problems. Jara Perez [11] and Zagar [23] reported that there were no adverse effects. Zagar (1988) and Gomez-Barreto (1998) showed that in the group treated with OM-85 BV, the duration of episodes was shorter than in the control group (Zagar: 6 days shorter; Gomez: 4 days shorter). In Schaad's study (1986), the duration of episodes was shorter in the control group (2 days). (We refrained from pooling the results of these strongly heterogeneous studies.)
Discussion
Our systematic review provides weak evidence that oral immunostimulation with bacterial extracts prevents ARTIs in children. There was a trend for fewer infections over 6 months of follow-up in children not in day care and a small reduction in number of antibiotic courses. Safety and tolerance of Bronchovaxom were good.
What are the limitations of this review? We think that searches and selection procedures were adequate. However, some important limitations of our review are related to the limited validity of the original trials. The overall quality of the trials was moderate to poor. While, for example, the included trials reported on clinically homogenous settings, treatment regimens and similar follow-up periods, important methodological items such as patient enrolment, generation of random sequence, concealment of treatment allocation and details about statistical analyses were seldom reported. Furthermore, most trials were of limited size. The problem with small trials is that they may generate treatment effects by random chance. Pharmaceutical companies sponsored ten of the trials; in one study, a co-author was working for the manufacturer. An association between competing interests and authors' conclusions has been shown [12] . In our meta-analysis, however, authors' conclusions per se were not considered. We do not know how potential competing interests may influence the way a clinical trial is designed and conducted or the way data are analysed and reported. The trials reported on a large variety of different endpoints. It was impossible to compare outcome data from more than three trials. Although the main endpoint, reduction of the number of infections, was reported in nine trials, differences in outcome definition (e.g. less than six vs. less than three infections) allowed combining the results of two trials only. Finally, data were too sparse to allow formal sensitivity analyses, addressing, for instance, the impact of treatment duration.
What are the implications for research? We think that further studies should examine which children benefit most. For example, otherwise healthy children reporting more than five ARTIs per six months before study inclusion could be studied. Furthermore, infants with chronic lung diseases or immunocompromised children should be enrolled because these populations are at very high risk for severe morbidity and have higher risk for mortality.
Conclusions
Evidence in favour of Bronchovaxom in the prevention of ARTIs in children is weak. There is a trend for fewer and shorter infections and a reduction of antibiotic use.
